Abstract
Kawasaki disease is an autoimmune vasculitis syndrome that occurs in children under 5 years of age.Its greatest harm is coronary artery disease, including coronary artery dilatation, coronary artery aneurysm and so forth.Moreover, myocardial infarction may occur in severe cases.In the acute phase of Kawasaki disease, high-dose intravenous immunoglobulin(IVIG)combined with aspirin can be used as the standard therapy for the treatment of Kawasaki disease, but 10% to 20% of the patients still have resistance to the initial IVIG treatment.There is an increased risk of coronary artery damage in these patients.Additional treatment is required for IVIG non-reactivity Kawasaki disease, and some new therapies are emerging, such as repeated use of IVIG, glucocorticoid and IL-1 receptor antagonists, etc.In the recovery period of Kawasaki disease, anticoagulant and prophylaxis therapy are the main choices, and surgical or interventional therapy may be performed as appropriate for the patients with severe coronary artery disease.This article reviews the research progress in the treatment of Kawasaki disease. Key words: Kawasaki disease; Intravenous immunoglobulin; Non-reactivity; Coronary artery lesion; Treatment
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
